Compound paracetamol and amantadine hydrochloride capsule and preparation method thereof
Through the coating technology of modified artificial beef yellow and modified chitosan derivative-gelatin, combined with the extrusion rounding process, the problem of difficult-to-control the viscosity and stability of artificial beef yellow in compound aminophenol alkamine capsules is solved, and a higher level of drug stability and efficacy.
Patent Information
- Application Number
- CN202411164148.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
AI Technical Summary
During the production process, existing compound alkaneamine capsules are difficult to control the viscosity of artificial beef and the stability of other drug ingredients, which affects the effectiveness of drugs and the stability of long-term storage.
Modified artificial beef yellow is prepared from artificial beef yellow and modified chitosan derivative-gelatin. The cross-linking reaction of modified chitosan derivative-gelatin and gelatin forms a hydrogel containing disulfide bonds, and is coated with artificial Beef yellow, and microspheres are prepared through extrusion and rounding process to improve the stability and efficacy of the drug.
It improves the stability and drug effect of compound aminophenol alkamine capsules, ensures the stability of the drug in the production process and the quality of long-term preservation, and enhances the sustainability of drug efficacy.
Smart Images

Figure BDA0005007336540000101 
Figure BDA0005007336540000111
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of medicines, and in particular to a compound acetaminophen capsule and a preparation method thereof. Background Art
[0002] Compound acetaminophen capsules are a commonly used over-the-counter drug, mainly used to relieve fever, headache, nasal congestion, sore throat and other symptoms caused by the common cold and influenza, and are also used for the prevention and treatment of influenza. The main ingredients of the drug include acetaminophen (antipyretic and analgesic), amantadine hydrochloride (antiviral), chlorpheniramine maleate (antiallergic drug), artificial bezoar (antipyretic and sedative effects) and caffeine (central stimulant, enhancing antipyretic and analgesic effects). These ingredients work together to effectively relieve cold and flu symptoms.
[0003] CN102861106A discloses a method for preparing a compound paracetamol and amantadine pellets, which is mainly made of the following raw materials: chlorpheniramine maleate, artificial bezoar, caffeine, amantadine hydrochloride, acetaminophen and dextrin; the preparation method includes: adding chlorpheniramine maleate and caffeine in the form of a solution, adding a dextrin aqueous solution, spraying the mixed masterbatch composed of acetaminophen, amantadine hydrochloride and artificial bezoar, and then spraying the remaining dextrin and the remaining mixed powder to prepare the compound paracetamol and amantadine pellets. Although the compound paracetamol and amantadine pellets prepared by the method are simple to operate, the method is difficult to control the viscosity of artificial bezoar and the stability of other effective drug components in the spraying production, which will affect the effect of the drug.
[0004] CN104311447A discloses a new crystal form of acetaminophen, a preparation method thereof and a compound acetaminophen and amantadine preparation. The invention improves the solubility of the new crystal form of acetaminophen by modifying acetaminophen. However, the compound acetaminophen and amantadine preparation prepared by the method has poor stability and its efficacy will be affected by long-term storage. Summary of the invention
[0005] In view of the above-mentioned defects of the prior art, the technical problem to be solved by the present invention is to improve the stability of the compound acetaminophen capsules and to improve the drug effect of the compound acetaminophen capsules.
[0006] To achieve the above object, the present invention provides a compound acetaminophen capsule, which comprises the following components in parts by weight: 200-300 parts of acetaminophen, 80-120 parts of amantadine hydrochloride, 1-5 parts of chlorpheniramine maleate, 10-18 parts of caffeine, 1-10 parts of starch, 0.5-5 parts of water-dispersible coating liquid, and 8-15 parts of modified artificial bezoar, wherein the modified artificial bezoar is prepared from artificial bezoar and modified chitosan derivative-gelatin.
[0007] Preferably, the preparation method of the modified artificial bezoar comprises the following steps, measured in parts by weight:
[0008] Step 1, adding 5-20 parts of artificial bezoar to 20-50 parts of ethanol to dissolve, to obtain an artificial bezoar ethanol solution;
[0009] Step 2: Add 20-50 parts of modified chitosan derivative-gelatin to the artificial bezoar ethanol solution in step 1, stir at 25-33° C. for 1-4 hours, and dry at 40-55° C. for 5-8 hours to obtain modified artificial bezoar.
[0010] Preferably, the method for preparing the modified chitosan derivative-gelatin comprises the following steps:
[0011] S1. Weigh the chitosan derivative, add 1-3wt% hydrochloric acid solution to prepare 2-4wt% chitosan hydrochloric acid solution, add modifier, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, seal, stir at room temperature for 2-4h, then transfer to a dialysis bag and dialyze with 3-5mmol / L hydrochloric acid solution 1-2 times in 1-2d under light-proof conditions, and dialyze with 3-5mmol / L hydrochloric acid solution plus 1-3wt% sodium chloride solution 2-3 times in 1-3d, pre-freeze the dialysate at low temperature for 12-20h, and then freeze-dry for standby use;
[0012] S2, weighing gelatin and 1-vinylimidazole, preparing a 1-3wt% gelatin solution with water, preparing a 1-vinylimidazole solution with water, pouring the prepared gelatin solution into a sealed device, and then adding the 1-vinylimidazole solution and the grafting agent mixture, stirring at 200-300rpm for 1-5h, and then transferring to a dialysis bag and dialyzing with 3-5mmol / L hydrochloric acid solution and 1-3wt% sodium chloride under light-proof conditions for 1-2d, and then dialyzing with 0.3-0.5mmol / L hydrochloric acid solution for 1-2d, pre-freezing the obtained solution for 12-20h, and then freeze-drying for standby use;
[0013] S3. Take the substances prepared in S1 and S2, dissolve them in a hydrochloric acid solution with a pH of 3-5, mix them evenly and dry them at room temperature to form a film, soak the film in a 0.1-0.3wt% sodium hydroxide solution for 3-5h, rinse it with water and then soak it in a 0.1-0.3wt% sodium hydroxide solution for 1-2h, finally rinse it with water and soak it for 1-3h, and dry it at room temperature to obtain a modified chitosan derivative - gelatin.
[0014] More preferably, the method for preparing the modified chitosan derivative-gelatin comprises the following steps, in parts by weight:
[0015] S1. Weigh 1-8 parts of chitosan derivative, add 100-250 parts of 1-3wt% hydrochloric acid solution to prepare 2-4wt% chitosan hydrochloric acid solution, add 1-9 parts of modifier and 3-10 parts of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, seal, stir at room temperature for 2-4h, then transfer to a dialysis bag and dialyze with 3-5mmol / L hydrochloric acid solution 1-2 times in 1-2d under light-proof conditions, and dialyze with 3-5mmol / L hydrochloric acid solution plus 1-3wt% sodium chloride solution 2-3 times in 1-3d, pre-freeze the dialysate at low temperature for 12-20h, and then freeze-dry for standby use;
[0016] S2, weigh 1-6 parts of gelatin and 1-5 parts of 1-vinylimidazole, prepare a 1-3wt% gelatin solution with water, and prepare a 1-vinylimidazole solution with 2-10 parts of water, pour the prepared gelatin solution into a sealing device, then add the 1-vinylimidazole solution and the grafting agent mixture, stir at 200-300rpm for 1-5h, then move into a dialysis bag and dialyze with 3-5mmol / L hydrochloric acid solution and 1-3wt% sodium chloride under light-proof conditions for 1-2d, and then dialyze with 0.3-0.5mmol / L hydrochloric acid solution for 1-2d, pre-freeze the resulting solution for 12-20h, and then freeze-dry for standby use;
[0017] S3. Take the substances prepared in S1 and S2, dissolve them in a hydrochloric acid solution with a pH of 3-5, mix them evenly and dry them at room temperature to form a film, soak the film in a 0.1-0.3wt% sodium hydroxide solution for 3-5h, rinse it with water and then soak it in a 0.1-0.3wt% sodium hydroxide solution for 1-2h, finally rinse it with water and soak it for 1-3h, and dry it at room temperature to obtain a modified chitosan derivative - gelatin.
[0018] Preferably, the modifier is any one of 2,2-dimethyl-3-mercaptopropionic acid, 3-mercaptoisobutyric acid, and N-acetyl-D-cysteine.
[0019] Preferably, the grafting agent is any one of α-ethyl-α-methyl-thiobutyrolactone, 2-oxo-tetrahydrothiophene-3-carboxaldehyde, and 5-ethyl-2-thiocyclopentanone.
[0020] More preferably, the grafting agent is 2-oxo-tetrahydrothiophene-3-carbaldehyde.
[0021] A method for preparing a compound acetaminophen capsule comprises the following steps, measured in parts by weight:
[0022] A1. Mixing to prepare a soft material: 200-300 parts of acetaminophen, 80-120 parts of amantadine hydrochloride, 1-5 parts of chlorpheniramine maleate, 10-18 parts of caffeine, 1-10 parts of starch, 0.5-5 parts of a water-dispersible coating liquid, and 8-15 parts of modified artificial bezoar are mixed uniformly to obtain a soft material;
[0023] A2. Extrusion and spheronization to prepare microspheres: The soft material in A1 is extruded into strips through an extrusion device with a sieve aperture of 1-2.5 mm, and microspheres are prepared through a spheronization device;
[0024] A3, drying to remove moisture and heat treatment;
[0025] A4. Whole particles are screened to obtain microspheres with a diameter less than 1.5 mm.
[0026] In this recipe, the ingredients and their functions are as follows:
[0027] Acetaminophen: Acetaminophen is a widely used over-the-counter antipyretic analgesic with significant analgesic and antipyretic effects.
[0028] Amantadine hydrochloride: Amantadine hydrochloride is an antiviral drug mainly used to prevent and treat respiratory infections caused by influenza A virus.
[0029] Chlorpheniramine maleate: Chlorpheniramine maleate, also known as chlorpheniramine, is a commonly used antihistamine that can relieve symptoms caused by allergic reactions, such as sneezing, runny nose, itchy eyes, watery tears, and itchy throat, by blocking histamine receptors.
[0030] Caffeine: Caffeine has a central excitatory effect, which can stimulate the central nervous system and improve the patient's alertness and attention. This is helpful in relieving the fatigue and drowsiness caused by colds or flu. It can work together with acetaminophen, chlorpheniramine maleate and other ingredients to comprehensively relieve the various symptoms caused by colds or flu.
[0031] Starch: As a common pharmaceutical excipient, starch is widely used as a filler. In the formula of compound acetaminophen capsules, starch can fill the gaps between active ingredients, so that the volume and weight of the entire preparation meet certain standards, which is convenient for the preparation's molding and subsequent processing.
[0032] Artificial bezoar: Artificial bezoar is a substitute for the traditional Chinese medicine bezoar, which has multiple pharmacological activities, such as clearing away heat and detoxification, anti-inflammatory, sedative, etc. In compound acetaminophen and amantadine capsules, artificial bezoar can work together with other active ingredients (such as acetaminophen, amantadine hydrochloride, etc.) to exert therapeutic effects and enhance the efficacy of the entire preparation.
[0033] Ethanol: Ethanol, as a solvent, can dissolve artificial bezoar and form a uniform artificial bezoar ethanol solution.
[0034] Chitosan derivatives: Chitosan derivatives are biocompatible and degradable cationic polysaccharides. They can be compounded with many anionic polyelectrolytes in various ways to form physiological environment responsive gels. At the same time, they have abundant active groups such as hydroxyl and amino groups. These groups can react with modifiers, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, etc., thereby introducing new functional groups or changing the properties of the original groups, providing the possibility for subsequent reaction with sodium carboxymethyl cellulose.
[0035] Hydrochloric acid: In the preparation process of modified chitosan derivative-gelatin, hydrochloric acid is used as a solvent to prepare chitosan hydrochloric acid solution and subsequent dialysate. This helps dissolve the chitosan derivative and carry out the modification reaction. At the same time, the addition of hydrochloric acid can adjust the pH value of the solution so that the reaction system remains within the appropriate pH range. This is very important for controlling the reaction conditions and ensuring the stability of the product.
[0036] Modifier: The modifier contains specific functional groups such as thiol and carboxyl. The carboxyl functional group can react with the amino group of the chitosan derivative under the activation of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to form an amide bond, thereby introducing the thiol functional group into the chitosan derivative modified by the modifier, providing a basis for the subsequent reaction with the gelatin modified by the grafting agent.
[0037] 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride: It mainly plays an activating and cross-linking role in the reaction between the modifier and carboxymethyl chitosan.
[0038] Sodium chloride: Sodium chloride is mixed with hydrochloric acid to adjust the ionic strength and osmotic pressure of the dialysate. This helps to more effectively remove unreacted substances, by-products and other impurities, and improve the purity of the product.
[0039] Gelatin: Gelatin contains amino functional groups. Through the modification process and the reaction with the grafting agent, its molecular structure changes, increasing the binding force with the chitosan derivative modified by its modifier. This enhanced binding force enables the modified gelatin to more effectively bind to artificial bezoar to form modified artificial bezoar.
[0040] 1-vinylimidazole: 1-vinylimidazole acts as a catalyst in the modification process of sodium carboxymethyl cellulose, which helps to accelerate the chemical reaction between sodium carboxymethyl cellulose and the grafting agent.
[0041] Grafting agent: The grafting agent is ring-opened under the catalytic action of 1-vinyl imidazole, and then reacts with active groups such as amine groups on the gelatin molecule. The gelatin modified by the grafting agent is then cross-linked with the chitosan derivative modified by the modifier, thereby preparing a modified chitosan derivative - gelatin.
[0042] Sodium hydroxide: Soaking the dried mixture in sodium hydroxide solution is mainly to neutralize the acidic substances (such as hydrochloric acid) that may remain in the film. This helps to stabilize the structure of the modified chitosan derivative-gelatin and reduce its acidic effects in subsequent applications. By soaking and rinsing with sodium hydroxide solution multiple times, impurities and unreacted substances can be further removed, and the purity of the modified chitosan derivative-gelatin can be improved.
[0043] Beneficial effects of the present invention:
[0044] 1. Compared with the prior art, the carboxyl group in the modifier is reacted with the amine group of the chitosan derivative to form an amide bond, thereby introducing a thiol group to form a thiol-modified chitosan derivative; at the same time, the grafting agent is ring-opened under the catalytic action to react with the amine group on the gelatin to form a thiol-modified gelatin; finally, the thiol-modified chitosan derivative and the thiol-modified gelatin are mixed to prepare a modified chitosan derivative-gelatin polymer containing a disulfide bond, and then the modified chitosan derivative-gelatin is used to coat artificial bezoar to obtain a modified artificial bezoar, which is beneficial to improve the stability of artificial bezoar in the production process, thereby improving the efficacy of the drug.
[0045] 2. Compared with the existing technology, by adopting the extrusion spheronization and inclusion process to prepare microspheres, the prepared capsule filling can have uniform particle size, good roundness and stable properties, thereby improving the overall quality and efficacy of the compound acetaminophen capsules. DETAILED DESCRIPTION
[0046] Parameters for specific chemical substances used, sources.
[0047] 2,2-dimethyl-3-sulfanylpropanoic acid, CAS No.: 35040-68-7.
[0048] N-Acetyl-D-cysteine, CAS number: 26117-28-2.
[0049] α-Ethyl-α-methyl-thiobutyrolactone, alpha-ethyl, alpha-methyl-thiobutyrolactone, CAS number: 103620-92-4.
[0050] 2-Oxo-tetrahydro-thiophene-3-carbaldehyde, CAS No.: 89463-76-3.
[0051] 5-ethyl-2-thiocyclopentanone, CAS No.: 201991-50-6.
[0052] Starch, corn starch.
[0053] 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, CAS number: 1892-57-5.
[0054] 1-vinylimidazole, CAS number: 1072-63-5.
[0055] Ethylcellulose aqueous dispersion, brand: ECD, FMC.
[0056] 4-Butylthiolactone, CAS number: 1003-10-7.
[0057] Example 1
[0058] A method for preparing compound paracetamol and amantadine capsules comprises the following steps:
[0059] A1. Mixing to prepare a soft material: 250 mg of acetaminophen, 100 mg of amantadine hydrochloride, 2 mg of chlorpheniramine maleate, 15 mg of caffeine, 2 mg of starch, 2 mg of ethyl cellulose aqueous dispersion, and 10 mg of modified artificial bezoar were mixed at 200 rpm for 10 min to obtain a soft material;
[0060] A2. Extrusion and spheronization to prepare microspheres: The soft material in A1 is extruded into strips through an extruder with a sieve hole diameter of 1.7 mm, and microspheres are prepared through a spheronization device;
[0061] A3. Drying to remove moisture and heat treatment: Drying in an oven at 25°C for 10 minutes.
[0062] A4. Whole the particles and screen out the microspheres with a diameter less than 1.5 mm to obtain the compound acetaminophen capsules.
[0063] Wherein, the preparation method of the modified artificial bezoar comprises the following steps:
[0064] Step 1: Add 10 g of artificial bezoar to 40 mL of ethanol to dissolve it to obtain an artificial bezoar ethanol solution;
[0065] Step 2: Add 45 g of modified chitosan derivative-gelatin to the artificial bezoar ethanol solution in step 1, stir at 25° C. for 2 h, and then dry at 55° C. for 6 h to obtain modified artificial bezoar.
[0066] In addition, the modified chitosan derivative-gelatin preparation method comprises the following steps:
[0067] S1. Weigh 3 g of carboxymethyl chitosan, add 100 mL of 1 wt% hydrochloric acid solution to prepare a 3 wt% chitosan hydrochloric acid solution, add 7 g of N-acetyl-D-cysteine and 5 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, seal with plastic wrap, stir at 22 ° C for 3 h, then transfer to a 14000 Da dialysis bag, dialyze with 5 mmol / L hydrochloric acid solution once within 1 day under light-proof conditions, and dialyze twice with 5 mmol / L hydrochloric acid solution plus 1 wt% sodium chloride solution within 2 days, pre-freeze the dialysate at -8 ° C for 12 h, and then freeze-dry for standby use;
[0068] S2. Weigh 3g of gelatin and 2g of 1-vinylimidazole, prepare a 3wt% gelatin solution with 100mL of water, and prepare a 1-vinylimidazole solution with 4mL of water. Pour the prepared gelatin solution into a four-necked flask, introduce nitrogen, add mechanical stirring, seal the other two flasks with rubber stoppers, and then take two syringes to draw the prepared 1-vinylimidazole solution and 3g of 1-vinylimidazole solution respectively. A mixture of 2-oxo-tetrahydrothiophene-3-carboxaldehyde in a molar ratio of 1:1 was prepared, and the syringes were inserted into the two stoppers respectively. Then, the 1-vinylimidazole solution and the 2-oxo-tetrahydrothiophene-3-carboxaldehyde mixture were added to the flask at the same time, and stirred at 200 rpm for 5 h. Then, the mixture was transferred into a 14000Da dialysis bag, and dialyzed for 1 day with a mixed solution of 0.3 mmol / L hydrochloric acid solution with a pH of 3.5 and a 0.1 mol / L sodium chloride solution under light-proof conditions, and then dialyzed for 1 day with a 0.3 mmol / L hydrochloric acid solution with a pH of 3.5. During this period, the dialyzate was changed every 12 h. Finally, the obtained solution was pre-frozen at -8 ° C for 12 h, and then freeze-dried for standby use;
[0069] S3. Take the substances prepared in S1 and S2, dissolve them in a hydrochloric acid solution with a pH of 3, mix them evenly and dry them at room temperature to form a film, soak the film in a 0.1wt% sodium hydroxide aqueous solution for 4 hours, rinse it with water and then soak it in a 0.1wt% sodium hydroxide aqueous solution for 1 hour, finally rinse it with water and soak it for 1 hour, and dry it at 25°C for 20 minutes to obtain a modified chitosan derivative - gelatin.
[0070] Example 2
[0071] The difference between Example 2 of the present application and Example 1 is that the N-acetyl-D-cysteine in Example 1 is replaced by 2,2-dimethyl-3-mercaptopropionic acid.
[0072] Example 3
[0073] The difference between Example 3 of the present application and Example 1 is that the N-acetyl-D-cysteine in Example 1 is replaced by 3-mercaptoisobutyric acid.
[0074] Example 4
[0075] The difference between Example 4 of the present application and Example 1 is that the 2-oxo-tetrahydrothiophene-3-carboxaldehyde in Example 1 is replaced by α-ethyl-α-methyl-thiobutyrolactone.
[0076] Example 5
[0077] The difference between Example 5 of the present application and Example 1 is that the 2-oxo-tetrahydrothiophene-3-carboxaldehyde in Example 1 is replaced by 5-ethyl-2-thiocyclopentanone.
[0078] Comparative Example 1
[0079] The difference between Comparative Example 1 of the present application and Example 1 is that the N-acetyl-D-cysteine in Example 1 is replaced by thioglycolic acid.
[0080] Comparative Example 2
[0081] The difference between Comparative Example 2 of the present application and Example 1 is that the 2-oxo-tetrahydrothiophene-3-carboxaldehyde in Example 1 is replaced by 4-butylthiolactone.
[0082] Test Example 1
[0083] Test of artificial bezoar bilirubin content:
[0084] Control solution: Accurately weigh 0.01032 g of bilirubin reference substance dried to constant weight at 105°C, place in a 100 mL brown volumetric flask, add chloroform to dissolve and dilute to the scale to make 0.1032 g mL -1 The solution is shaken and set aside.
[0085] Test solution: Take 21 capsules of the products prepared in Examples 1-5 and Comparative Examples 1-2, accurately weigh, grind, accurately weigh an appropriate amount (equivalent to 10 mg of artificial bezoar), place in a 50 mL brown volumetric flask, add 40 mL of chloroform-methanol-water-hydrochloric acid (volume ratio of 90:10:0.3:0.03), ultrasonicate for 10 min, quickly cool to room temperature, add the above solution to dilute to the scale, shake well, filter, and filter the filtrate through a 0.45 μm microporous membrane to obtain the result.
[0086] Stability test: The same test solution was measured at 0, 2, 4, 6, 8 and 10 hours after preparation. The RSD calculated by the bilirubin peak area was 1.5%, indicating that the test solution had good stability within 10 hours.
[0087] Sample recovery test: Accurately measure 30 mL of the reference solution, place it in a 100 mL brown volumetric flask, add chloroform to dilute to the scale for later use. Weigh 9 portions of the products prepared in Examples 1-5 and Comparative Examples 1-2, accurately weigh 1.2 g, divide them into three groups, add 4.0, 5.0, and 6.0 mL of the above-mentioned reference solution, and determine the relative peak area according to the method for preparing the test solution, calculate, and then calculate the average value of the three groups.
[0088] Accelerated stability test: The compound paracetamol and amantadine capsules prepared in Examples 1-5 and Comparative Examples 1-2 were subjected to an accelerated test under conditions of 40°C and 75% relative humidity. The bilirubin recovery rate was tested at 1, 2, 3 and 6 months of acceleration. The test results are shown in Table 1:
[0090] Table 1 Bilirubin recovery rate and accelerated recovery rate
[0091]
[0092] Test Example 2
[0093] According to the 2015 edition of the Chinese Pharmacopoeia, the capsule dissolution adopts the first method of the basket method, taking the samples prepared in Examples 1-5 and Comparative Examples 1-2, according to the dissolution determination method, using pH 1.2 hydrochloric acid solution (9 mL is diluted with water to 1000 mL) 1000 mL as the solvent, the speed is 100 rpm, and the operation is carried out according to the law. 5 mL (with the above hydrochloric acid solution) is sampled at 3, 6, 10, 15, and 20 minutes respectively, filtered, and 1 mL of the filtrate is accurately measured, placed in a 50 mL volumetric bottle, 0.1 mol / L sodium hydroxide is added to the scale, and the absorbance is measured at a wavelength of 257 nm by spectrophotometry, and the dissolution is calculated according to the absorption coefficient of acetaminophen (C8H9NO2) 715. The test results are shown in Table 2:
[0094] Table 2 Dissolution of acetaminophen
[0095] Experimental groups Acetaminophen dissolution (%) Example 1 97.8 Example 2 82.5 Example 3 84.6 Example 4 85.4 Example 5 84.7 Comparative Example 1 78.3 Comparative Example 2 76.8
[0096] Test Example 3
[0097] Compound acetaminophen capsule content uniformity test: Take 1 capsule of the product prepared in Example 1-5 and Comparative Example 1-2, pour the contents into a 250mL volumetric flask, add mobile phase to dissolve chlorpheniramine maleate and dilute to the scale, shake well, and filter; determine the content according to the method under the content determination item, which should comply with the regulations (Part 4 of the 2020 edition of the Chinese Pharmacopoeia). If A+2.2S≤15.0, the content uniformity of the test sample meets the regulations; if A+S>15.0, the content uniformity of the test sample does not meet the regulations; if A+2.2S>15.0 and A+S≤15.0, take another 20 capsules for retesting, and the test results are shown in Table 3:
[0098] Table 3 Content uniformity test
[0099]
[0100]
[0101] Artificial bezoar has antipyretic and sedative effects, and artificial bezoar is mainly made of ox bile powder, bile acid, hyodeoxycholic acid, taurine, bilirubin, cholesterol, etc. Therefore, the bilirubin index in artificial bezoar is measured to determine the content of artificial bezoar.
[0102] Through the test data results in Test Examples 1-3 and Tables 1 to 3, it can be found that the compound acetaminophen capsules prepared in Example 1 have the best stabilizer, safety, and drug effect.
[0103] Comparing the data in the table 2 of Examples 1-3 and Comparative Example 1, it is found that the dissolution and stability data in Example 1 are different, which may be due to the use of different modifiers. The modifier contains carboxyl functional groups and thiol functional groups. The role of the modifier is that the carboxyl functional group in the modifier can react with the amino group of the chitosan derivative under the activation of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to form an amide bond, and then the thiol functional group is introduced into the chitosan derivative to obtain a thiol-modified chitosan derivative; similarly, the grafting agent containing the thiol functional group is introduced into gelatin to obtain thiol-modified gelatin; finally, the thiol-modified chitosan derivative and the thiol-modified gelatin are cross-linked to obtain a modified chitosan derivative-gelatin hydrogel containing a disulfide bond. The disulfide bond hydrogel has good stability in water, is not easy to lose or decompose, and can effectively maintain its structure and performance stability. At the same time, the modified chitosan derivative-gelatin hydrogel also has good biocompatibility. Since artificial bezoar raw materials have high viscosity and unstable chemical properties, the process of preparing compound acetaminophen capsules is relatively complicated. In the production process, it is necessary not only to control the temperature but also to reduce the viscosity of the materials, and it is easy to cause instability of key qualities such as the efficacy period and disintegration time, affecting the therapeutic effect. Therefore, the use of modified chitosan derivatives-gelatin to coat artificial bezoar can reduce the problems of large viscosity and unstable chemical properties of artificial bezoar raw materials during processing, which makes the production process complicated. Then, the modified artificial bezoar is used as a raw material to prepare compound acetaminophen capsules, thereby improving the stability of bezoar.
[0104] The modifier in Example 1 contains, in addition to carboxyl functional groups and sulfhydryl functional groups, an amino functional group, which can react with the aldehyde functional group contained in 2-oxo-tetrahydrothiophene-3-carboxaldehyde in Example 1 to further generate a dynamic covalent imine bond, thereby making the modified chitosan derivative-gelatin have the advantages of good toughness and fast self-healing speed. The tough hydrogel provides a stable supporting environment for artificial bezoar. The three-dimensional network structure of the hydrogel can effectively wrap and protect the artificial bezoar, prevent it from being physically or chemically damaged in an in vitro environment, and then improve the drug stability of the capsule. Therefore, the compound paracetamol and amantadine capsule prepared in Example 1 has the best stability, is not easily destroyed by the external environment, can prolong the shelf life of the drug, and makes the drug better play its drug effect. Comparative Examples 1-3 and Comparative Example 1, because no dynamic covalent imine bond is further generated to increase the protectiveness of bezoar, the modified artificial bezoar in Example 1 has the best stability.
[0105] The reason for the difference in the dissolution rate of acetaminophen in capsules may be the stability or uniformity of auxiliary materials or other raw materials such as modified artificial bezoar mixed with acetaminophen. Because the outer layer of modified artificial bezoar is modified chitosan derivative-gelatin, it has very strong hydrophilicity and can absorb and keep a large amount of moisture. When acetaminophen is mixed with modified artificial bezoar, modified artificial bezoar can absorb the moisture in the dissolution medium rapidly, forming a moist environment, which is conducive to the dissolution and release of acetaminophen. Meanwhile, these hydrogels with three-dimensional network structure may form porous structures in the swelling process, and these pores can be used as channels for drug release, increase the contact area of drug and dissolution medium, thereby improving the dissolution rate of medicine. Because there is no further generation of imine bond hydrogel in Test Example 2-3 and Comparative Example 1, and the stability of the hydrogel containing only disulfide bonds is poor, the dissolution rate of acetaminophen in the compound acetaminophen amantadine capsule in implementation 1 is high.
[0106] Comparative Example 1, Table 2 data in embodiment 4-5 and Comparative Example 2, find that the dissolution and stability data in embodiment 1 are different, and the reason may be that different grafting agents have been used.The effect of grafting agent is as mentioned above, and the grafting agent in embodiment 1 also contains aldehyde group except containing the ring that can react with amino group.The dynamic covalent imine bond generated by aldehyde group and amino reaction is compared with the disulfide bond hydrogel that only contains in embodiment 4,5 and Comparative Example 2 and further increases the dynamic covalent imine bond, so the three-dimensional network structure of hydrogel is firmer, shows more excellent stability, and then artificial bezoar is protected more closely, improves the stability of artificial bezoar, and hydrophilic stable hydrogel network comrades also increase the dissolution of other drugs such as acetaminophen simultaneously, and then makes compound acetaminophen capsule show good drug effect.Therefore the compound acetaminophen capsule prepared in embodiment 1 has good stability, good drug effect, and safety.
Claims
1. A compound acetaminophen capsule, characterized in that: The invention comprises the following components in parts by weight: 200-300 parts of acetaminophen, 80-120 parts of amantadine hydrochloride, 1-5 parts of chlorpheniramine maleate, 10-18 parts of caffeine, 1-10 parts of starch, 0.5-5 parts of water-dispersible coating liquid, and 8-15 parts of modified artificial bezoar. The modified artificial bezoar is prepared from artificial bezoar and modified chitosan derivative-gelatin.
2. The compound acetaminophen capsule according to claim 1, characterized in that: The preparation method of the modified artificial bezoar comprises the following steps, measured in parts by weight: Step 1, adding 5-20 parts of artificial bezoar to 20-50 parts of ethanol to dissolve, to obtain an artificial bezoar ethanol solution; Step 2: Add 20-50 parts of modified chitosan derivative-gelatin to the artificial bezoar ethanol solution in step 1, stir at 25-33° C. for 1-4 hours, and dry at 40-55° C. for 5-8 hours to obtain modified artificial bezoar.
3. The compound acetaminophen capsule according to claim 2, characterized in that: The preparation method of the modified chitosan derivative-gelatin comprises the following steps: S1. Weigh the chitosan derivative, add 1-3wt% hydrochloric acid solution to prepare 2-4wt% chitosan hydrochloric acid solution, add modifier, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, seal, stir at room temperature for 2-4h, then transfer to a dialysis bag and dialyze with 3-5mmol / L hydrochloric acid solution 1-2 times in 1-2d under light-proof conditions, and dialyze with 3-5mmol / L hydrochloric acid solution plus 1-3wt% sodium chloride solution 2-3 times in 1-3d, pre-freeze the dialysate at low temperature for 12-20h, and then freeze-dry for standby use; S2, weighing gelatin and 1-vinylimidazole, preparing a 1-3wt% gelatin solution with water, preparing a 1-vinylimidazole solution with water, pouring the prepared gelatin solution into a sealed device, and then adding the 1-vinylimidazole solution and the grafting agent mixture, stirring at 200-300rpm for 1-5h, and then transferring to a dialysis bag and dialyzing with 3-5mmol / L hydrochloric acid solution and 1-3wt% sodium chloride under light-proof conditions for 1-2d, and then dialyzing with 0.3-0.5mmol / L hydrochloric acid solution for 1-2d, pre-freezing the obtained solution for 12-20h, and then freeze-drying for standby use; S3. Take the substances prepared in S1 and S2, dissolve them in a hydrochloric acid solution with a pH of 3-5, mix them evenly and dry them at room temperature, soak them in a 0.1-0.3wt% sodium hydroxide solution for 3-5h, rinse them with water and then soak them in a 0.1-0.3wt% sodium hydroxide solution for 1-2h, finally rinse them with water and soak them for 1-3h, and dry them at room temperature to obtain a modified chitosan derivative - gelatin.
4. The compound acetaminophen capsule according to claim 3, characterized in that: The preparation method of the modified chitosan derivative-gelatin comprises the following steps, calculated by weight: S1. Weigh 1-8 parts of chitosan derivative, add 100-250 parts of 1-3wt% hydrochloric acid solution to prepare 2-4wt% chitosan hydrochloric acid solution, add 1-9 parts of modifier and 3-10 parts of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, seal, stir at room temperature for 2-4h, then transfer to dialysis bag and dialyze with 3-5mmol / L hydrochloric acid 1-2 times in 1-2d under light-proof conditions, and dialyze with 3-5mmol / L hydrochloric acid plus 1-3wt% sodium chloride solution 2-3 times in 1-3d, pre-freeze the dialysate at low temperature for 12-20h, and then freeze-dry for standby use; S2, weigh 1-6 parts of gelatin and 1-5 parts of 1-vinylimidazole, prepare a 1-3wt% gelatin solution with water, and prepare a 1-vinylimidazole solution with 2-10 parts of water, pour the prepared gelatin solution into a sealing device, then add the 1-vinylimidazole solution and the grafting agent mixture, stir at 200-300rpm for 1-5h, then move into a dialysis bag and dialyze with 3-5mmol / L hydrochloric acid solution and 1-3wt% sodium chloride under light-proof conditions for 1-2d, and then dialyze with 0.3-0.5mmol / L hydrochloric acid for 1-2d, pre-freeze the resulting solution for 12-20h, and then freeze-dry for standby use; S3. Take the substances prepared in S1 and S2, dissolve them in a hydrochloric acid solution with a pH of 3-5, mix them evenly and dry them at room temperature, soak them in a 0.1-0.3wt% sodium hydroxide solution for 3-5h, rinse them with water and then soak them in a 0.1-0.3wt% sodium hydroxide solution for 1-2h, finally rinse them with water and soak them for 1-3h, and dry them at room temperature to obtain a modified chitosan derivative - gelatin.
5. The compound acetaminophen capsule according to claim 3, characterized in that: The modifier is any one of 2,2-dimethyl-3-mercaptopropionic acid, 3-mercaptoisobutyric acid, and N-acetyl-D-cysteine.
6. The compound acetaminophen capsule according to claim 3, characterized in that: The grafting agent is any one of α-ethyl-α-methyl-thiobutyrolactone, 2-oxo-tetrahydrothiophene-3-carboxaldehyde, and 5-ethyl-2-thiocyclopentanone.
7. The compound acetaminophen capsule according to claim 6, characterized in that: The grafting agent is 2-oxo-tetrahydrothiophene-3-carboxaldehyde.
8. The method for preparing the compound acetaminophen capsule according to any one of claims 1 to 7, characterized in that: The method comprises the following steps, in parts by weight: A1. Mixing to prepare a soft material: 200-300 parts of acetaminophen, 80-120 parts of amantadine hydrochloride, 1-5 parts of chlorpheniramine maleate, 10-18 parts of caffeine, 1-10 parts of starch, 0.5-5 parts of a water-dispersible coating liquid, and 8-15 parts of modified artificial bezoar are mixed uniformly to obtain a soft material; A2. Extrusion and spheronization to prepare microspheres: The soft material in A1 is extruded into strips through an extrusion device with a sieve aperture of 1-2.5 mm, and microspheres are prepared through a spheronization device; A3, drying to remove moisture and heat treatment; A4. Whole particles are screened to obtain microspheres with a diameter less than 1.5 mm.
9. Use of the compound acetaminophen capsule according to any one of claims 1 to 7 in cold medicines.
